RecruitingPhase 1Phase 2NCT03508752

Neurocognitive Decline in Patients With Brain Metastases

Phase I/II Trial to Determine the Neurocognitive Decline in Patients With Multiple (>6) Brain Metastases Treated With Distributed Stereotactic Radiosurgery

Sponsor

University of Texas Southwestern Medical Center

Enrollment

80 participants

Start Date

Dec 5, 2017

Study Type

INTERVENTIONAL

Conditions

Brain Metastases

Summary

The phase I component of the study is to identify maximal tolerated dose (MTD). The phase II is to evaluate neurocognitive decline.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This trial is studying the effects of radiation treatment on thinking and memory in patients who have cancer that has spread to the brain in 6 or more spots, with the goal of finding better ways to treat brain metastases while protecting brain function. **You may be eligible if...** - You are 18 years or older - Your cancer (any solid tumor type except germ cell cancer) has spread to the brain in 6 or more spots - The largest tumor is 4 cm or smaller - You have not previously had radiation to these specific brain areas - You are in reasonable health and can carry out basic self-care - You are using contraception if you could become pregnant **You may NOT be eligible if...** - You have previously had whole-brain radiation therapy - Your largest brain tumor is over 4 cm - You have fewer than 6 brain metastases - You are unable to understand or sign a consent form Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.